Agios Pharmaceuticals Insider Sells $102K in Shares

Insider sale represents 3.53% decrease in ownership stake

Apr. 6, 2026 at 10:13pm

Got story updates? Submit your updates here. ›

An extreme close-up of complex financial machinery and equipment, conveying a sense of institutional power and security without depicting any literal currency or financial symbols.An insider's sale of Agios Pharmaceuticals shares highlights the need to monitor insider transactions for insights into a company's performance.Cambridge Today

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Sarah Gheuens sold 2,940 shares of the company's stock on April 2nd, 2026. The shares were sold at an average price of $34.71, for a total value of $102,047.40. Following the transaction, Gheuens now owns 80,277 shares in the company, valued at approximately $2,786,414.67.

Why it matters

Insider transactions can provide insight into a company's performance and management's confidence. This sale represents a 3.53% decrease in Gheuens' ownership stake, which may signal a shift in her outlook on Agios Pharmaceuticals.

The details

The sale was executed under a pre-arranged Rule 10b5-1 trading plan and was made to cover tax withholding obligations related to the vesting of equity awards. Agios Pharmaceuticals is a biopharmaceutical company focused on developing cancer and rare genetic disease treatments.

  • The transaction occurred on Thursday, April 2nd, 2026.

The players

Sarah Gheuens

An insider at Agios Pharmaceuticals who sold 2,940 shares of the company's stock.

Agios Pharmaceuticals, Inc.

A biopharmaceutical company headquartered in Cambridge, Massachusetts that focuses on developing cancer and rare genetic disease treatments.

Got photos? Submit your photos here. ›

The takeaway

This insider sale highlights the need for investors to closely monitor insider transactions, as they can provide valuable insights into a company's performance and management's outlook.